Mizuho Increases STAAR Surgical (NASDAQ:STAA) Price Target to $55.00

STAAR Surgical (NASDAQ:STAA) had its target price boosted by Mizuho from $53.00 to $55.00 in a research report released on Wednesday, Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Several other research analysts have also issued reports on STAA. Needham & Company LLC reaffirmed a hold rating on shares of STAAR Surgical in a research note on Thursday, April 4th. Stifel Nicolaus reiterated a buy rating and set a $50.00 price target on shares of STAAR Surgical in a research report on Monday, April 1st. Canaccord Genuity Group lifted their price target on shares of STAAR Surgical from $32.00 to $46.00 and gave the stock a hold rating in a research report on Monday, April 8th. William Blair upgraded shares of STAAR Surgical from a market perform rating to an outperform rating in a research report on Thursday, April 4th. Finally, Piper Sandler lowered their price target on shares of STAAR Surgical from $40.00 to $33.00 and set a neutral rating for the company in a research report on Tuesday, February 27th. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical presently has an average rating of Hold and a consensus price target of $47.13.

STAAR Surgical Stock Performance

Shares of STAA opened at $41.02 on Wednesday. The business’s fifty day moving average price is $42.13 and its two-hundred day moving average price is $35.87. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 95.40 and a beta of 0.80. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $68.27.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.12). The firm had revenue of $77.40 million for the quarter, compared to analyst estimates of $75.34 million. STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $0.05 EPS. As a group, research analysts forecast that STAAR Surgical will post 0.03 EPS for the current year.

Insider Activity at STAAR Surgical

In other news, Director Aimee S. Weisner acquired 1,750 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was purchased at an average price of $38.11 per share, for a total transaction of $66,692.50. Following the completion of the acquisition, the director now owns 10,864 shares in the company, valued at $414,027.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently made changes to their positions in STAA. New York State Teachers Retirement System increased its holdings in STAAR Surgical by 3.5% during the 3rd quarter. New York State Teachers Retirement System now owns 58,340 shares of the medical instruments supplier’s stock worth $2,344,000 after purchasing an additional 1,979 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in STAAR Surgical by 17.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,639 shares of the medical instruments supplier’s stock valued at $347,000 after buying an additional 1,259 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in STAAR Surgical by 2.8% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 14,400 shares of the medical instruments supplier’s stock valued at $579,000 after acquiring an additional 391 shares in the last quarter. Perigon Wealth Management LLC acquired a new position in STAAR Surgical during the 3rd quarter worth approximately $265,000. Finally, Nisa Investment Advisors LLC boosted its position in STAAR Surgical by 415.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,445 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 1,971 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.